nimesulide in COVID-19 infection

The role of Nimesulide in the treatment of COVID-19 infection

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200723048178N1

Enrollment

Registered

2020-07-28

Start date

2020-07-28

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 infection. COVID-19

Interventions

Intervention group: Nimesulide 100 mg twice daily for five days.

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: The participant is willing and able to give informed consent for participation in the study and agrees with the study protocol Not previously diagnosed with COVID-19 infection or treated. Adults = 12 years

Exclusion criteria

Exclusion criteria: The participant is allergic to any of the study group Inability to be followed up for the trial period Already taking an NSAID or Nimesulide Participants with a contraindication to any of the drugs including Active bleeding, Recent Myocardial infarction (last three months), or Peptic ulcer disease

Design outcomes

Primary

Measure	Time frame
Percent change in the oxygen saturation, hospitalization, or death. Timepoint: 1 week. Method of measurement: Oxygen saturation is measured via pulse oximeter.	—

Countries

Pakistan

Contacts

Public ContactAhmed Farhan

Shaheed Zulfiqar Ali Mdical University

drfarhan992@gmail.com+92 51 2331590

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026